Inflammatory white blood cells in semen is related to semen quality affecting fertility. The role of inflammatory cells on the seminal levels of various cytokines associated with inflammation and sperm motility is evaluated. Semens from 10 healthy males and 20 chronic prostatitis patients were evaluated for the levels of interleukin(IL)-1a, IL-6, IL-8 and tumor necrosis factor(TNF)-a. Motility parameters were recorded using Hamilton-Thorne computer semen analysis system. Sperm motility parameters such as including average path velocity(VAP), straight line velocity(VSL), curvilinear velocity(VCL), lateral head displacement(ALH), beat frequency(BCF), straightness(STR), linearity(LIN), elongation and area in control and chronic prostatitis patients were 44.9+/-2.5/38.8+/-1.3(um/sec), 36.4+/-2.4/30.5+/-1.1(um/sec), 64.2+/-3.9/ 58.0+/-2.4(Fm/sec), 3.3+/-0.2/4.8+/-0.3tm), 19.8+/-3.7/13.9+/-0.3(Hz), 77.7+/-5.1/78.8+/-1.2(%), 50.6+/-17.5/53.5+/-1.9(%), 66.8+/-5.4/57.8+/-1.1(9%), 2.9+/-0.3/3.8+/-0.1(um/sec), respectively. Statistical significance was noted in VAP, VSL, ALH, BCF, elongation and area. Semen levels of IL-1a, IL-6, IL-8 and TNF-a in control and chronic prostatitis patients are 15.1+/-1.5/52.9+/-14.2 (pg/ml), 10.5+/-2.2/38.3+/-12.2 (pg/ml), 1.60+/-0.38/ 6.02+/-0.26 (ug/L), 11.8+/-2.5 / 21.7+/-4.0(pg/ml) statistically significant in all. For combined parameters, the correlation coefficient of IL-1a and VSL, ALH, Area were 0.40, 0.41, 0.37 respectively which were significant. The correlation coefficient of IL-8 and VAP, VSL, VCL, ALH, BCF, Elongation, Area were 0.48, 0.49, 0.39, 0.41, 0.55, 0.59, 0.66 respectively which were also significant. Seminal inflammatory cytokines are present in increased quantities if inflammatory white blood cells are present in semen and this increase might be related to sperm motility.
Cytokines* ; Fertility ; Head ; Humans ; Inflammation ; Interleukin-6 ; Interleukin-8 ; Leukocytes ; Male ; Necrosis ; Prostatitis ; Semen ; Semen Analysis ; Sperm Motility* ; Spermatozoa*

OBJECTIVETo explore the significance of interleukin-6 (IL-6) and IL-8 in the diagnosis of neonatal sepsis.

METHODSThis was a prospective study conducted between August 2014 and February 2015. A total of 140 neonates who were suspected infectious were enrolled and classified into a sepsis group (n=49) and a local infection group (n=91). Sixty-one neonates who were non-infectious served as the control group. Serum levels of IL-6 and IL-8 were measured before treatment and 3 days after treatment. The value of serum IL-6 and IL-8 for the diagnosis of neonatal sepsis was assessed by receiver operating characteristic (ROC) curve analysis.

RESULTSBefore treatment, serum levels of IL-6 and IL-8 in the sepsis group were higher than those in the local infection and control groups (P<0.05), and the local infection group had higher serum levels of IL-6 and IL-8 than the control group (P<0.05). After three days of treatment, the serum IL-6 level in the sepsis group remained higher than that in the local infection and control groups (P<0.05), and the local infection group had higher serum level of IL-6 than the control group (P<0.05). There was no significant difference in the serum IL-8 level among the three groups. According to the ROC curve, when the cut-off value of serum IL-6 was 32 pg/mL, the sensitivity, specificity and accuracy of serum IL-6 for the diagnosis of neonatal sepsis were 87.8%, 79.6% and 81.6% respectively; when the cut-off value of serum IL-8 was 54 pg/mL, the sensitivity, specificity and accuracy of serum IL-6 for the diagnosis of neonatal sepsis were 77.6%, 63.8% and 67.2% respectively. With the combination of serum IL-6 and IL-8 levels, the sensitivity, specificity and accuracy for the diagnosis of neonatal sepsis were 71.4%, 86.2% and 82.6% respectively.

CONCLUSIONSIL-6 and IL-8 participate in the inflammatory response and the serum levels of both vary with the severity of infection. The diagnostic value of IL-6 for neonatal sepsis is higher than IL-8. The combined detection of serum levels IL-6 and IL-8 may increase the accuracy of diagnosis of neonatal sepsis.

C-Reactive Protein ; analysis ; Female ; Humans ; Infant, Newborn ; Interleukin-6 ; blood ; Interleukin-8 ; blood ; Male ; ROC Curve ; Sepsis ; blood ; diagnosis

Cerebral Palsy ; diagnosis ; etiology ; physiopathology ; Hearing Disorders ; etiology ; Humans ; Interleukin-6 ; analysis ; Prognosis ; Research Report

OBJECTIVE: To evaluate the value of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for assessing disease activity in patients with rheumatoid arthritis (RA) treated with tofacitinib. METHODS: This retrospective study was conducted among 98 RA patients in active stage treated with tofacitinib in Third Xiangya Hospital and 100 healthy control subjects from the Health Management Center of the hospital from 2019 to 2021. We collected blood samples from all the participants for measurement of erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6) and other blood parameters 1 month before and 6 months after tofacitinib treatment. We further evaluated PLR and NLR before and after tofacitinib treatment in the RA patients, and analyzed their correlations with RA disease activity. RESULTS: PLR and NLR increased significantly in RA patients as compared with the healthy controls. In the RA patients, PLR and NLR were positively correlated with the levels of hs- CRP, ESR, IL- 6, Disease Activity Score of 28 joints-ESR (DAS28-ESR), anti-cyclic citrullinated peptide (CCP), and rheumatoid factor (RF) before and after tofacitinib treatment. Tofacitinib treatment for 6 months significantly decreased hs-CRP, ESR, IL-6, CCP, RF and DAS28-ESR levels in the RA patients. CONCLUSION NLR and PLR can be useful biomarkers for assessing disease activity in RA patients treated with tofacitinib.
Humans ; Neutrophils ; Retrospective Studies ; C-Reactive Protein/analysis* ; Interleukin-6/metabolism* ; Arthritis, Rheumatoid ; Lymphocytes

OBJECTIVE: Interlukin-6 (IL-6) increases platelet count during inflammation and may act in a manner similar to thrombopoietin. Tocilizumab is a monoclonal antibody of the IL-6 receptor and widely used in the treatment of rheumatoid arthritis (RA). Here, we evaluated the incidence of tocilizumab-induced thrombocytopenia and clinical factors associated with the development of thrombocytopenia. METHODS: Patients with RA, who were treated with tocilizumab and had exposed to other biologics previously in a tertiary hospital between January 2014 and December 2017, were retrospectively evaluated. We compared occurrence of thrombocytopenia between tocilizumab and previous biologics. Furthermore, the factors associated with thrombocytopenia were analyzed using logistic regression analysis. RESULTS: In total, 114 patients with RA were treated with tocilizumab for mean 90.5 weeks (interquartile range, 30.9~174.9). Thrombocytopenia was reported in 14 patients (12.3%) and it was higher rate compared with previous biologics. Most cases were grade 1 thrombocytopenia. Multivariate analysis showed that patient age (odds ratio [OR], 2.170; 95% confidence interval [CI], 1.118~4.211; p=0.022) and platelet count prior to treatment with tocilizumab (OR, 0.972; 95% CI, 0.954~0.990; p=0.002) were significantly associated with the development of thrombocytopenia. CONCLUSION: Old age is risk factor for developing tocilizumab-induced thrombocytopenia and higher platelet count prior to treatment is associated with lowering risk of development of thrombocytopenia. However, thrombocytopenia was tolerable.
Antibodies ; Arthritis, Rheumatoid ; Biological Products ; Humans ; Incidence ; Inflammation ; Interleukin-6 ; Logistic Models ; Multivariate Analysis ; Platelet Count ; Receptors, Interleukin-6 ; Retrospective Studies ; Risk Factors ; Tertiary Care Centers ; Thrombocytopenia ; Thrombopoietin

OBJECTIVETo study the levels and roles of cytokines TNF-α, IL-6 and IL-10 in bronchoalveolar lavage fluid (BALF) in children with Mycoplasma pneumoniae pneumonia (MPP).

METHODSThe levels of TNF-α, IL-6 and IL-10 in BALF were measured using ELISA in children with MPP at acute stage (n=45) and at remission stage (n=30). Twenty children without lung lesions severed as the control group.

RESULTSThe TNF-α, IL-6 and IL-10 levels in BALF were higher in children with MPP at acute stage than those in the control group (P<0.05). The levels of TNF-α and IL-6 in BALF at remission stage were reduced to the levels similar to the control group and were significantly lower than those at the acute stage in children with MPP. However, the levels of IL-10 in BALF remained at higher levels at remission stage in children with MPP.

CONCLUSIONSThe levels of TNF-α, IL-6 and IL-10 in BALF increase in children with MPP at acute stage, suggesting that the cytokines may be involved in the pathogenesis of MPP.

Adolescent ; Bronchoalveolar Lavage Fluid ; immunology ; Child ; Child, Preschool ; Female ; Humans ; Interleukin-10 ; analysis ; Interleukin-6 ; analysis ; Male ; Pneumonia, Mycoplasma ; etiology ; immunology ; Tumor Necrosis Factor-alpha ; analysis

OBJECTIVE: The current progress of the molecular biological study is in the situation of documentation of relation between the tumor development and the gene mutation. We report an analysis of gene expression profiling of meningioma by cDNA chip. METHODS: Meningioma, tumor attached dura and normal dura were obtained during surgery. RNA was extracted from each specimen and cDNA microarray was done. After that, we confirmed the reliability of results from the microarray technique by RT-PCR. RESULTS: We examined the expression of the tumor related gene by cDNA chip. The genes showing two fold changes in the expression were analyzed to find the difference between two groups. The analysis of the tumor and tumor attached dura indicated that the expression of twenty four genes were increased and seventeen genes were decreased in the tumor. The analysis of the gene expression of tumor and normal dura showed increase in twenty seven genes and decrease in thirty one genes. Nine genes in the tumor showed more increase than those in the tumor attached dura and the normal dura. We performed RT-PCR using cytokines to confirm the reliability of the microarray result. CONCLUSION: The cDNA chip contributes as a good laboratory method to check various gene expression of the meningioma and the dura. In the future, the relationship between the expression of IL-1beta, IL-4, IL-6, IL-8, and the function of each gene are required to investigate.
Cytokines ; DNA, Complementary* ; Gene Expression Profiling* ; Gene Expression* ; Interleukin-4 ; Interleukin-6 ; Interleukin-8 ; Meningioma* ; Oligonucleotide Array Sequence Analysis ; Reproducibility of Results ; RNA

BACKGROUND/AIMS: This study evaluated the effect of Helicobacter pylori eradication on functional dyspepsia (FD), and the relationship between the changes of histological gastritis and FD symptom responses. METHODS: A total of 213 FD patients diagnosed by Rome III criteria were consecutively enrolled. H. pylori tests and gastritis grade by the Sydney system were performed before and 1 year after the proton pump based-eradication therapy for 7 days. Serum levels of pepsinogen, and genetic polymorphisms IL-6, IL-8 and IL-10 were investigated. RESULTS: Total of 91 patients completed the 1 year follow-up. When the response rate of dyspepsia was compared at 1 year between the non-eradicated group (n = 24) and eradicated group (n = 67), each group showed complete response of 62.5% and 62.7%; satisfactory response (> or = 50%) of 0.0% and 19.4%; partial response (< 50%) of 12.5% and 11.9%; and refractory response of 25.0% and 6.0%, respectively (P = 0.015). In addition, the responder group (complete + satisfactory response) at 1 year showed improvement of activity and chronic inflammation in both the antrum and corpus (all P < 0.001). Multivariate analysis showed that H. pylori eradication (OR, 5.81; 95% CI, 1.07-31.59) and symptom improvement at 3 month (OR, 28.90; 95% CI, 5.29-157.82) were associated with the improvement of dyspepsia at 1 year. Among the successfully eradicated FD patients (n = 67), male (P = 0.013) and higher initial BMI (P = 0.016) were associated with the improvement of dyspepsia at 1 year. CONCLUSIONS: H. pylori eradication improved FD symptoms, as well as gastritis at 1 year, suggesting that inflammation mediates FD.
Dyspepsia ; Follow-Up Studies ; Gastritis ; Helicobacter ; Helicobacter pylori ; Humans ; Inflammation ; Interleukin-10 ; Interleukin-6 ; Interleukin-8 ; Male ; Multivariate Analysis ; Pepsinogen A ; Polymorphism, Genetic ; Proton Pumps ; Rome

OBJECTIVETo investigate the feasibility of Ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance angiography (USPIO-MRA) combined with interleukin-6 (IL-6) and IL-10 detection for detecting atherosclerotic plaques in rabbits.

METHODSTwenty-four normal male rabbits were randomly assigned (n=8) into group A with atherosclerosis induced by damaging the aortic tunica intima with Foley's tube in combination with a high fat diet, group B with a high fat diet, and group C without any intervention. At week 12, plain and USPIO-MRA was performed in all the 24 rabbits and the results were compared with pathological examinations; blood samples were collected from the ear vein to examine blood lipids and levels of IL-6 and IL-10.

RESULTSThe rabbits in groups A and B showed significantly different IL-6 levels (167 ± 21.3 vs 116 ± 14.3 pg/ml, P<0.05) but comparable blood lipids and IL-10 levels (P>0.05). The levels of IL-6, IL-10, TC, TG, and LDL, but not HDL, differed significantly between groups A and C and between groups B and C (P<0.01). Continuous MRA scan showed significantly different signal-to-noise ratios (SNR) between the 3 groups.

CONCLUSIONUSPIO-MRA combined with IL-6 and IL-10 detection is feasible in detecting atherosclerotic plaques in rabbits.

Animals ; Atherosclerosis ; Contrast Media ; Dextrans ; Interleukin-10 ; analysis ; Interleukin-6 ; analysis ; Magnetic Resonance Angiography ; Magnetite Nanoparticles ; Male ; Plaque, Atherosclerotic ; diagnosis ; Rabbits

Blood Cell Count ; Bone Marrow Cells ; pathology ; Child ; Cytokines ; analysis ; Fever ; Histiocytosis, Non-Langerhans-Cell ; metabolism ; pathology ; therapy ; Humans ; Interleukin-2 ; analysis ; Interleukin-6 ; analysis ; Receptors, Interleukin-1 ; analysis